Retrospective and molecular biological data suggest that sunitinib may be effective in patients with non-clear cell renal cell carcinoma (nccRCC).Methods
Eligibility criteria included advanced nccRCC except for collecting duct carcinoma and sarcomatoid carcinoma without identifiable renal cell carcinoma subtypes. Patients were treated with 50 mg/day oral sunitinib for 4 weeks, followed by 2 weeks of rest. The primary end point was the overall response rate.Results
Thirty-one eligible patients were enrolled. Twenty-four patients (77%) had prior nephrectomy. By Memorial Sloan-Kettering Cancer Center criteria, 8 patients (26%) had poor risk and 14 (45%) had intermediate risk. Twenty-two patients had papillary RCC, and 3 had chromophobe RCC. Eleven patients had partial response, with a response rate of 36% (95% CI, 19–52%) and an additional 17 patients (55%) had stable disease. The median duration of response was 12.7 months (95% CI: 6.3–19.1 months), and the median progression-free survival was 6.4 months (95% CI: 4.2–8.6 months). At a median follow-up duration of 18.7 months (95% CI: 13.7–23.7 months), 13 patients (42%) had died, resulting in an estimated median survival of 25.6 months (95% CI: 8.4–42.9 months). Toxicity profiles were commensurate with prior reports.Conclusions
Sunitinib has promising activity in patients with nccRCC. (NCT01219751) Final survival results will be reported in the meeting.